• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • Experts on Demand
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Sale!
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

The World Market for Cancer Therapeutics: Forecasts to 2020 (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment

$2,100.00 – $4,200.00

Clear
SKU: KLI5752001 Categories: Cancer Treatment Reports, Pharmaceuticals Market Research, Vaccines Market Reports Pages: 320
  • Description
  • Table of Contents
  • Latest reports

Description

This report, the World Market for Cancer Therapeutics presents a detailed picture of the market for cancer drugs, with a focus on novel therapies. The market analysis in this report includes analysis of products avaiable for each cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Colon Cancer and Other types) including Monoclonal Antibodies, Tyrosine Kinase, Inhibitors, Cancer Vaccines, Cytokines, Gene Therapy, Traditional Chemotherapy.

The report has a special emphasis on novel treatments and provides an overview of treatments on the market and in development for each cancer type. Trend analysis, market share and company profiles of over 50 major players, smaller participants and new entrants is a part of the market analysis in this report.

Secondary and primary research was used to determine market size for cancer types by product sales in this report. Methodology included telephone interviews and email correspondence with company representatives, researchers, government representatives, and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 20 5. Historical data was provided for the years 20 0 through 20 4, with forecast data provided for 20 6 through 2020. Compound annual growth rates (CAGRs) are provided for the 20 0-20 5, 20 5-2020 and 20 0-2020 periods for each segment covered. Competitive analysis is provided for the year 20 5. The forecasted market analysis for 20 5-2020 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, cancer epidemiology, and demographic trends.

Companies covered include Novartis, Pfizer, Abbvie, Bayer, Merck and many other companies.

Table of Contents

ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Size and Growth of the Market

TWO: INTRODUCTION, NOVEL AND TRADITIONAL APPROACHES

What is Cancer

Biochemistry of Cancer Cells

Carcinogen Metabolism

Causes of Cancer Growth

History and Growth of the Cancer Treatment Market

How Personalized Medicine is Changing the Cancer Market

Targeted Cancer Therapy

Genetic Testing in Cancer

Industry Structure

Cancer Treatment Approaches: Traditional vs. Novel

Product Examples

Monoclonal Antibodies

Tyrosine Kinase Inhibitors

Cancer Vaccines

Cytokines

Gene Therapy

Other Novel Classifications

THREE: MARKET DRIVERS / BARRIERS

Global Cancer Impact

Life Expectancy and Cancer

The United States – The Real Cost of Cancer

Curing Cancer⎯The Ultimate Goal

The Cost of Cancer Therapies

Healthy People 2020

Marketing and Distribution Trends

Elderly Clinical Trial Involvement

Development Risk

Development Risk in Novel Cancer Therapy Research⎯Allovectin-7

Development Programs

What Does the Novel Therapy Development Pipeline Look Like?

Recent NDA Activity

New Indications

Reaching the Market: Regulatory Accelerated Approvals and Priority Reviews

Development and Marketing Agreements

Insurance and Reimbursement Issues

FOUR: NOVEL THERAPIES IN BLADDER CANCER TREATMENT

Bladder Cancer Overview

Trends in Incidence and Mortality

Treating Bladder Cancer

Novel Treatment Research Activities

Developer Participation

Bladder Cancer Treatment Market and Opportunity

Novel Treatment Outlook

FIVE: NOVEL THERAPIES IN BRAIN CANCER TREATMENT

Brain Cancer Overview

Trends in Incidence and Mortality

Treating Brain Cancer

Novel Treatment Research Activities

Developer Participation

Brain Cancer Treatment Market and Opportunity

Novel Treatment Outlook

SIX: NOVEL THERAPIES IN BREAST CANCER TREATMENT

Breast Cancer Overview

Trends in Incidence and Mortality

Treating Breast Cancer

Novel Treatment Research Activities

Developer Participation

Breast Cancer Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

SEVEN: NOVEL THERAPIES IN COLORECTAL CANCER TREATMENT115

Colorectal Cancer Overview

Trends in Incidence and Mortality

Treating Colorectal Cancer

Novel Treatment Research Activities

Developer Participation

Colorectal Cancer Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

EIGHT: NOVEL THERAPIES IN KIDNEY CANCER TREATMENT

Kidney Cancer Overview

Trends in Incidence and Mortality

Treating Kidney Cancer

Novel Treatment Research Activities

Developer Participation

Kidney Cancer Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

NINE: NOVEL THERAPIES IN LEUKEMIA TREATMENT

Leukemia Cancer Overview

Trends in Incidence and Mortality

Treating Leukemia

Novel Treatment Research Activities

Developer Participation

Leukemia Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

TEN: NOVEL THERAPIES IN LIVER CANCER TREATMENT

Liver Cancer Overview

Trends in Incidence and Mortality

Treating Liver Cancer

Novel Treatment Research Activities

Developer Participation

Liver Cancer Treatment Market and Opportunity

Novel Treatment Outlook

ELEVEN: NOVEL THERAPIES IN LUNG CANCER TREATMENT

Lung Cancer Overview

Trends in Incidence and Mortality

Treating Lung Cancer

Novel Treatment Research Activities

Developer Participation

Lung Cancer Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

TWELVE: NOVEL THERAPIES IN LYMPHOMA TREATMENT

Lymphoma Overview

Trends in Incidence and Mortality

Treating Lymphoma

Novel Treatment Research Activities

Developer Participation

Lymphoma Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

Figure 12-8

THIRTEEN: NOVEL THERAPIES IN MELANOMA TREATMENT

Melanoma Overview

Trends in Incidence and Mortality

Treating Melanoma

Novel Treatment Research Activities

Developer Participation

Melanoma Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

FOURTEEN: NOVEL THERAPIES IN MULTIPLE MYELOMA TREATMENT

Myeloma Overview

Trends in Incidence and Mortality

Treating Multiple Myeloma

Novel Treatment Research Activities

Developer Participation

Multiple Myeloma Treatment Market and Opportunity

Novel Treatment Outlook

Leading Products and Suppliers

FIFTEEN: NOVEL THERAPIES IN PANCREATIC CANCER TREATMENT229

Pancreatic Cancer Overview

Trends in Incidence and Mortality

Treating Pancreatic Cancer

Novel Treatment Research Activities

Developer Participation

Pancreatic Cancer Treatment Market and Opportunity

Novel Treatment Outlook and Suppliers’ Market Impact

SIXTEEN: NOVEL THERAPIES IN PROSTATE CANCER TREATMENT 239

Prostate Cancer Overview

Trends in Incidence and Mortality

Treating Prostate Cancer

Novel Treatment Research Activities

Developer Participation

Prostate Cancer Treatment Market and Opportunity

Novel Treatment Outlook and Suppliers’ Market Impact

SEVENTEEN: NOVEL CANCER THERAPIES: MARKET SUMMARY

Overview

How Have Novel Therapies Shaped the Market and What’s In store for the Future?252

Novel Therapies and its Impact on Individual Cancer Markets

Geographical Market and Trends

Competitive Landscape

EIGHTEEN: MARKET PARTICIPANTS AND KEY DEVELOPERS

Introduction

AbbVie

Acerta Pharma

Adaptimmune

Advantagene

Altor BioScience

Amgen

Apceth GmbH & Co. KG

Array BioPharma

Astex Pharmaceuticals

AstraZeneca plc

Bayer

Bellicum Pharmaceuticals, Inc.

BioCancell Ltd.

Bluebird Bio

Boehringer Ingelheim

Boston Biomedical

Bristol-Myers Squibb Company

Caladrius (NeoStem)

Celgene

Celldex Therapeutics

Celsion Corporation

Clovis Oncology

Cold Genesys, Inc.

Daiichi Sankyo

Eisai

Eli Lilly & Company

EMD Serono

Galena Biopharma

Gamida Cell

Genprex, Inc.

Gilead Sciences

Immunomedics

Incyte

Inovio

Johnson & Johnson

Juno Therapeutics

Karyopharm Therapeutics

MaxiVAX

MedImmune

Merck & Company

Millennium (Takeda Oncology)

Momotaro-Gene, Inc.

MultiVir, Inc.

Northwest Biotherapeutics

Novartis

Oncolytics Biotech

OncoMed

OncoSec Medical, Inc.

Pfizer, Inc.

Roche

Sanofi

Seattle Genetics

Sevion Therapeutics

Takara Bio

Tocagen

VBL Therapeutics

ZIOPHARM Oncology, Inc.

INFORMATION SOURCES

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

Figure 1-1

Cancer Therapeutics Market, 2010-2020

Table 1-1

Novel Cancer Therapies Market, 2010-2020

Figure 1-2

Novel Cancer Therapies Market, 2010-2020

TWO: CANCER INDUSTRY DEVELOPMENT

Table 2-1

Viruses Associated with Cancer in Humans

Figure 2-1

Approved Cancer Therapies in the United States by Primary Indication

Figure 2-2

Market Value for Traditional vs. Novel Cancer Therapies

Figure 2-3

Market Distribution: Traditional vs. Novel Cancer

Figure 2-4

Leading Chemotherapy Treatments by 2015 Estimated Sales

Figure 2-5

Leading Hormone Cancer Treatments by 2015 Estimated Sales

Figure 2-6

Antibody Conjugates in Development by Phase

Figure 2-7

Antibody Conjugates in Development by Cancer Type

THREE: MARKET DRIVERS / BARRIERS

Table 3-1

Global Cancer Incidence by Selected Types of Cancer, 2012 and 2025, all races, all

ages, both genders

Figure 3-1

Estimated and Projected Global Cancer Incidence by Selected Types of Cancer, 2012

and 2025

Table 3-2

Most Common Cancer by Region and Gender

Table 3-3

Five-year Net Survival Rates* (%) for Selected Cancers among Adults 15 Years of Age

and Older in Select Countries, Average 2005-2009

Figure 3-2

United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both

Sexes, 2009

Figure 3-3

United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both

Sexes, 2009

Figure 3-4

Novel Cancer Compounds in Development by Phase of Development

Figure 3-5

Novel Therapy Developments by Cancer Type

Figure 3-6

Phase III: Novel Cancer Compounds in Development for Major Indications,

Distribution Estimates

Figure 3-7

Phase II: Novel Cancer Compounds in Development for Major Indications, Distribution

Estimates

Figure 3-8

Phase I: Novel Cancer Compounds in Development for Major Indications, Distribution

Estimates

Table 3-4

Select NDA Activity: 2015

Table 3-5

Select New Indications, 2015

FOUR: NOVEL THERAPIES IN BLADDER CANCER TREATMENT

Figure 4-1

Global Incidence and Mortality of Bladder Cancer by Country, 2012

Figure 4-2

Research Activities in Novel Bladder Cancer Treatment by Classification

Figure 4-3

Bladder Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 4-4

Global Bladder Cancer Treatment Market, 2010-2020

Figure 4-5

Distribution of Sales by Broad Classification: Bladder Cancer Treatments, 2015

Figure 4-6

Novel Treatments for Bladder Cancer by Drug Classification, 2010-2020

FIVE: NOVEL THERAPIES IN BRAIN CANCER TREATMENT

Figure 5-1

Global Incidence and Mortality of Brain Cancer by Country, 2012

Figure 5-2

Research Activities in Novel Brain Cancer Treatment by Classification

Figure 5-3

Brain Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 5-4

Global Brain Cancer Treatment Market, 2010-2020

Figure 5-5

Distribution of Sales by Broad Classification: Brain Cancer Treatments, 2015

Figure 5-6

Novel Treatments for Brain Cancer by Drug Classification, 2010-2020

SIX: NOVEL THERAPIES IN BREAST CANCER TREATMENT

Figure 6-1

Global Incidence and Mortality of Breast Cancer by Country, 2012

Figure 6-2

Research Activities in Novel Breast Cancer Treatment by Classification

Figure 6-3

Breast Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 6-4

Global Breast Cancer Treatment Market, 2010-2020

Figure 6-5

Distribution of Sales by Broad Classification: Breast Cancer Treatments, 2015

Figure 6-6

Novel Treatments for Breast Cancer by Drug Classification, 2010-2020

Figure 6-7

Leading Novel Products in Breast Cancer Treatment based on Revenues, 2010-2015 111

Figure 6-8

Leading Novel Products in Breast Cancer Treatment based on Revenues, Market Share,

Estimated 2015

Figure 6-9

Breast Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,

Estimated 2015

SEVEN: NOVEL THERAPIES IN COLORECTAL CANCER TREATMENT

Figure 7-1

Global Incidence and Mortality of Colorectal Cancer by Country, 2012

Figure 7-2

Research Activities in Novel Colorectal Cancer Treatment by Classification

Figure 7-3

Colorectal Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase

of Development

Figure 7-4

Global Colorectal Cancer Treatment Market, 2010-2020

Figure 7-5

Distribution of Sales by Broad Classification: Colorectal Cancer Treatments, 2015

Figure 7-6

Novel Treatments for Colorectal Cancer by Drug Classification, 2010-2020

Table 7-7

Leading Novel Products in Colorectal Cancer Treatment based on Revenues, 2010-2015126

Figure 7-8

Leading Novel Products in Colorectal Cancer Treatment based on Revenues, Market

Share, Estimated 2015

Figure 7-9

Colorectal Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,

Estimated 2015

EIGHT: NOVEL THERAPIES IN KIDNEY CANCER TREATMENT

Figure 8-1

Global Incidence and Mortality of Kidney Cancer by Country, 2012

Figure 8-2

Research Activities in Novel Kidney Cancer Treatment by Classification

Figure 8-3

Kidney Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 8-4

Global Kidney Cancer Treatment Market, 2010-2020

Figure 8-5

Distribution of Sales by Broad Classification: Kidney Cancer Treatments, 2015

Figure 8-6

Novel Treatments for Kidney Cancer by Drug Classification, 2010-2020

Table 8-7

Leading Novel Products in Kidney Cancer Treatment based on Revenues, 2010-2015138

Figure 8-8

Leading Novel Products in Kidney Cancer Treatment based on Revenues, Market

Share, Estimated 2015

Figure 8-9

Kidney Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,

Estimated 2015

NINE: NOVEL THERAPIES IN LEUKEMIA TREATMENT

Table 9-1

Leukemia Overview by Type

Figure 9-1

Distribution of Leukemia Cases by Type

Figure 9-2

Global Incidence and Mortality of Leukemia by Country, 2012

Figure 9-3

Research Activities in Novel Leukemia Treatment by Classification

Figure 9-4

Leukemia Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 9-5

Global Leukemia Treatment Market, 2010-2020

Figure 9-6

Distribution of Sales by Broad Classification: Leukemia Treatments, 2015

Figure 9-7

Novel Treatments for Leukemia by Drug Classification, 2010-2020

Figure 9-8

Leading Novel Products in Leukemia Treatment based on Revenues, 2010-2015

Figure 9-9

Leading Novel Products in Leukemia Treatment based on Revenues, Market Share,

Estimated 2015

Figure 9-10

Leukemia Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated

2015

TEN: NOVEL THERAPIES IN LIVER CANCER TREATMENT

Figure 10-1

Global Incidence and Mortality of Liver Cancer by Country, 2012

Figure 10-2

Research Activities in Novel Liver Cancer Treatment by Classification

Figure 10-3

Liver Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 10-4

Global Liver Cancer Treatment Market, 2010-2020

Figure 10-5

Distribution of Sales by Broad Classification: Liver Cancer Treatments, 2015

ELEVEN: NOVEL THERAPIES IN LUNG CANCER TREATMENT

Table 11-1

Types of Primary Lung Cancer

Figure 11-1

Global Incidence and Mortality of Lung Cancer by Country, 2012

Figure 11-2

Research Activities in Novel Lung Cancer Treatment by Classification

Figure 11-3

Lung Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 11-4

Global Lung Cancer Treatment Market, 2010-2020

Figure 11-5

Distribution of Sales by Broad Classification: Lung Cancer Treatments, 2015

Figure 11-6

Novel Treatments for Lung Cancer by Drug Classification, 2010-2020

Figure 11-7

Leading Novel Products in Lung Cancer Treatment based on Revenues, 2010-2015.. 181

Figure 11-8

Leading Novel Products in Lung Cancer Treatment based on Revenues, Market Share,

Estimated 2015

Figure 11-9

Lung Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues,

Estimated 2015

TWELVE: NOVEL THERAPIES IN LYMPHOMA TREATMENT

Table 12-1

Classification of Non-Hodgkin’s Lymphomas

Figure 12-1

Global Incidence and Mortality of Lymphoma by Country, 2012

Figure 12-2

Research Activities in Novel Lymphoma Treatment by Classification

Figure 12-3

Lymphoma Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 12-4

Global Lymphoma Treatment Market, 2010-2020

Figure 12-5

Distribution of Sales by Broad Classification: Lymphoma Treatments, 2015

Figure 12-6

Novel Treatments for Lymphoma by Drug Classification, 2010-2020

Figure 12-7

Leading Novel Products in Lymphoma Treatment based on Revenues, 2010-2015

Lymphoma Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated

2015

THIRTEEN: NOVEL THERAPIES IN MELANOMA TREATMENT

Table 13-1

Malignant Conditions of the Skin

Figure 13-1

Global Incidence and Mortality of Melanoma by Country, 2012

Figure 13-2

Research Activities in Novel Melanoma Treatment by Classification

Figure 13-3

Melanoma Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 13-4

Global Melanoma Treatment Market, 2010-2020

Figure 13-5

Distribution of Sales by Broad Classification: Melanoma Treatments, 2015

Figure 13-6

Novel Treatments for Melanoma by Drug Classification, 2010-2020

Figure 13-7

Leading Novel Products in Melanoma Treatment based on Revenues, 2010-2015

Figure 13-8

Leading Novel Products in Melanoma Treatment based on Revenues, Market Share,

Estimated 2015

Figure 13-9

Melanoma Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated

2015

FOURTEEN: NOVEL THERAPIES IN MULTIPLE MYELOMA

TREATMENT

Figure 14-1

Global Incidence and Mortality of Multiple Myeloma by Country, 2012

Figure 14-2

Research Activities in Novel Multiple Myeloma Treatment by Classification

Figure 14-3

Multiple Myeloma Potential Targeted/Novel Therapies Development Pipeline by Phase

of Development

Figure 14-4

Global Multiple Myeloma Treatment Market, 2010-2020

Figure 14-5

Distribution of Sales by Broad Classification: Multiple Myeloma Treatments, 2015 .. 223

Figure 14-6

Novel Treatments for Multiple Myeloma by Drug Classification, 2010-2020

Table 14-7

Leading Novel Products in Multiple Myeloma Treatment based on Revenues, 2010-

2015

Figure 14-8

Multiple Myeloma Novel Therapies: Leading Suppliers Shares by Market Revenues,

Estimated 2015

FIFTEEN; NOVEL THERAPIES IN PANCREATIC CANCER TREATMENT229

Figure 15-1

Global Incidence and Mortality of Pancreatic Cancer by Country, 2012

Figure 15-2

Research Activities in Novel Pancreatic Cancer Treatment by Classification

Figure 15-3

Pancreatic Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase

of Development

Figure 15-4

Global Pancreatic Cancer Treatment Market, 2010-2020

Figure 15-5

Distribution of Sales by Broad Classification: Pancreatic Cancer Treatments, 2015

Figure 15-6

Novel Treatments for Pancreatic Cancer by Drug Classification, 2010-2020

SIXTEEN: NOVEL THERAPIES IN PROSTATE CANCER TREATMENT 239

Figure 16-1

Global Incidence and Mortality of Prostate Cancer by Country, 2012

Figure 16-2

Research Activities in Novel Prostate Cancer Treatment by Classification

Figure 16-3

Prostate Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of

Development

Figure 16-4

Global Prostate Cancer Treatment Market, 2010-2020

Figure 16-5

Distribution of Sales by Broad Classification: Prostate Cancer Treatments, 2015

Figure 16-6

Novel Treatments for Prostate Cancer by Drug Classification, 2010-2020

SEVENTEEN: NOVEL CANCER THERAPIES: MARKET SUMMARY

Table 17-1

Novel Cancer Therapies, Global Market Value by Classification, 2010-2020

Figure 17-1

Novel Cancer Therapies, Global Market Value by Classification, 2010-2020

Figure 17-2

Novel Cancer Therapies, Market Share by Classification of Treatment, 2015

Figure 17-3

Novel Therapy Potential by Cancer Type, 2015 and 2020 Estimates

Figure 17-4

Distribution of Novel Cancer Therapy Potential in Cancer, by Type, 2020

Figure 17-4

Novel Cancer Therapy Market by Broad Region, 2015 Estimated Distribution

Table 17-2

Novel Cancer Therapy Market, Leading Suppliers’ Shares by Market Revenues, 2015263

Figure 17-5

Novel Cancer Therapy Market, Leading Suppliers’ Market Share, 2015

EIGHTEEN: MARKET PARTICIPANTS AND KEY DEVELOPERS

Figure 18-1

Novel Cancer Therapies in Development for Leading Companies

INFORMATION SOURCES

 

    The 2019 Worldwide Market for Targeted Cancer Therapeutics
    April 16, 2019
    Vaccines 2018: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others)
    August 8, 2018
    Potential “Pipeline Disruptors” – New Products That Will Drive The Future Pharmaceutical Market
    May 15, 2017
    The World Market for Cancer Therapeutics: Forecasts to 2020 (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment
    November 12, 2015

Related products

  • Placeholder image

    Emerging Cancer Vaccine Market, The

    $3,500.00 – $7,000.00
  • Placeholder image

    Cardiovascular Disease: The 45 Market in the United States for Drugs and Medical Devices

    $2,995.00 – $5,990.00
  • Placeholder image

    The Market for Lead Optimization Tools and Services: Applying the New “Omics” to Enhance Drug Discovery

    $1,875.00 – $3,750.00
  • Placeholder image

    Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline

    $3,500.00 – $7,000.00

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • How Globalization and Climate Change Impact COVID-19 and the IVD Market September 20, 2023
  • IVD Trends 2023-2028: Emerging Growth Markets in Asia, Latin America, and the Middle East September 15, 2023
  • Worldwide IVD: 8 Key Trends to Watch in $106 Billion Market September 6, 2023
  • The Wide-Reaching Potential of Artificial Intelligence in Healthcare August 28, 2023
  • IVD for Pets: A $2.7 Billion Global Market July 24, 2023

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
QIAGEN: Company ProfileTransdermal and Transmucosal Drug Delivery Markets: Forecasts to 2020
Scroll to top